Intelligent Bio Solutions Inc. - Common Stock (INBS)
2.3300
+0.2900 (14.22%)
Intelligent Bio Solutions Inc. is a biotechnology company focused on delivering innovative solutions in the field of drug testing and biomonitoring
The company specializes in developing non-invasive tests that leverage advanced technology to provide rapid, accurate, and reliable results. By utilizing its proprietary platform, Intelligent Bio Solutions aims to enhance workplace safety, improve public health monitoring, and facilitate more efficient drug testing processes across various sectors, including healthcare and law enforcement. Their commitment to innovation positions them at the forefront of the evolving landscape of bioanalytics.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Intelligent Bio Solutions reports rising sales and profit margins, driven by recurring revenue from cartridge sales and global expansion through key partnerships.
Intelligent Bio Solutions stock surges with increased trading volume, driven by progress on its FDA 510(k) submission. The company, specializing in non-invasive testing, advances clinical trials and reports significant growth in drug screening system installations.
INBS stock results show that Intelligent Bio Solutions beat analyst estimates for earnings per share but missed on revenue for the third quarter of 2024.
Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions.
Shares of Big Lots, Inc. (NYSEBIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1.
